Parameter
| Biomarker | C-reactive protein (CRP) | Full name | C-reactive protein | Molecular Type | Protein (acute phase reactive protein) |
|---|---|---|---|---|---|
| Molecular Formula | Human CRP: C₂₄₄H₃₇₆N₆₈O₇₆S₆ | Molecular Weight | ~25.1 kDa | Core Functional Dimensions | Assessment of systemic inflammatory status |
| Disease | Inflammatory Bowel Disease (IBD) | Disease Subtypes | / | ||
| Organ | Intestine | Test Sample / Technology Platform | Plasma/serum (immunoturbidimetric assay, ELISA, chemiluminescence assay) | ||
| Pathobiological Mechanisms | 1. It is synthesized by hepatocytes under the regulation of proinflammatory cytokines such as IL-6 and TNF-α, and rapidly increases within 4-6 hours of inflammatory activation in IBD; 2. Amplifying systemic inflammatory response by activating complement system (C1q/C3) and promoting phagocyte chemotaxis; (3) The level of CRP is positively correlated with the severity of intestinal mucosal inflammation. When CRP > 45mg/L, the risk of colectomy in CD patients increases by 3 times | ||||
| Clinical Availability Status | Clinical routine application | ||||
| Notes and Dynamics | (1) The Guideline for the diagnosis and Treatment of IBD recommended CRP combined with fecal calprotectin (FC) for the differential diagnosis of IBD and IBS, with a specificity of 91%. (2) The latest study showed that the dynamic change rate of CRP (≥50% within 2 weeks of treatment) could predict the 1-year sustained response rate of anti-TNF therapy with an accuracy of 78% | ||||